<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-2-8-2-2">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Long-term follow-up after immunosuppressive therapy: <br />US recommendations
			</div>


			<div class="content-container">

				<img class="center-img" src="media/images/slide_2-8-2-2/picture1.png" alt="" style="margin-top:60px">

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Long-term follow-up after immunosuppressive therapy: USÂ recommendations</header>
				
			<ul>
				<li><span>Responders are followed for relapse and cytogenetic abnormalities</span></li>
				<li><span>However, there is no consensus on the definition of relapse</span>
					<ul>
						<li><span>The NHLBI defines relapse as the point at which reintroduction of immunosuppression is required for decreasing blood counts, with or without blood product transfusion</span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185 </span></li>
			</ul>

		</div>


		

	</div>
</div>